Moneycontrol PRO

Buy Dr Reddy's Laboratories; target of Rs 4750: ICICI Direct

ICICI Direct is bullish on Dr Reddy's Laboratories has recommended buy rating on the stock with a target price of Rs 4750 in its research report dated July 29, 2022.

July 31, 2022 / 01:50 PM IST
  • bselive
  • nselive
Todays L/H

ICICI Direct's research report on Dr Reddy's Laboratories

Dr Reddy’s (DRL) portfolio includes pharmaceutical generics, APIs, custom pharmaceutical services, biosimilar and complex formulations. Revenue breakup: US (35%), India (20%), Russia and CIS (14%), Europe (8%), RoW (8%), PSAI (14%) and others (2%) • It has 13 formulation facilities, nine API manufacturing facilities, one biologics facility and several R&D centres across the globe.


We value Dr Reddy’s at Rs 4750 i.e. 24x FY24E EPS of Rs 191 + NPV of Rs 167.8 for gRevlimid.


For all recommendations report, click here

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on are their own, and not that of the website or its management. advises users to check with certified experts before taking any investment decisions.

Dr. Reddy's Laboratories - 290722 - ic

Broker Research
first published: Jul 31, 2022 01:50 pm
ISO 27001 - BSI Assurance Mark